FI113767B - Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa - Google Patents

Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa

Info

Publication number
FI113767B
FI113767B FI965021A FI965021A FI113767B FI 113767 B FI113767 B FI 113767B FI 965021 A FI965021 A FI 965021A FI 965021 A FI965021 A FI 965021A FI 113767 B FI113767 B FI 113767B
Authority
FI
Finland
Prior art keywords
nervous system
central nervous
dopaminergic activity
benzimidazole derivatives
activity
Prior art date
Application number
FI965021A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI965021A0 (fi
FI965021A (fi
Inventor
Anton F Fliri
Brian T O'neill
William S Faraci
Mark A Sanner
Stevin H Zorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI965021A0 publication Critical patent/FI965021A0/fi
Publication of FI965021A publication Critical patent/FI965021A/fi
Application granted granted Critical
Publication of FI113767B publication Critical patent/FI113767B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI965021A 1994-06-14 1996-12-13 Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa FI113767B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25970794A 1994-06-14 1994-06-14
PCT/IB1995/000285 WO1995034555A1 (fr) 1994-06-14 1995-04-24 Derives de la benzimidazolone a activite dopaminergique centrale

Publications (3)

Publication Number Publication Date
FI965021A0 FI965021A0 (fi) 1996-12-13
FI965021A FI965021A (fi) 1996-12-13
FI113767B true FI113767B (fi) 2004-06-15

Family

ID=22986031

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965021A FI113767B (fi) 1994-06-14 1996-12-13 Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa

Country Status (11)

Country Link
EP (1) EP0765320B1 (fr)
JP (1) JP2860604B2 (fr)
AT (1) ATE206708T1 (fr)
CA (1) CA2192975C (fr)
DE (1) DE69523155T2 (fr)
DK (1) DK0765320T3 (fr)
ES (1) ES2163506T3 (fr)
FI (1) FI113767B (fr)
MX (1) MX9606450A (fr)
PT (1) PT765320E (fr)
WO (1) WO1995034555A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A3 (fr) * 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EP1177792A3 (fr) * 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
MXPA03002329A (es) * 2000-09-19 2003-10-15 Boehringer Ingelheim Pharma Nuevos derivados de bencimidazolona que muestran afinidad por los receptores de serotonina y dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (fr) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2008000760A1 (fr) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
EP2054041A2 (fr) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations de flibansérine et leur procédé de fabrication
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
JP2018112616A (ja) 2017-01-10 2018-07-19 富士フイルム株式会社 積層体、積層体の製造方法、および車両用ルームミラー
TW202202493A (zh) * 2020-05-06 2022-01-16 美商默沙東藥廠 Il4i1抑制劑及使用方法
EP4308119A1 (fr) * 2021-03-19 2024-01-24 Centre National de la Recherche Scientifique <sup2/>? <sub2/>?7?applications de ligands polarisés du récepteur 5-htde la sérotonine pour le traitement de la douleur, de la sclérose en plaques et le contrôle de la thermorégulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
JP2860604B2 (ja) 1999-02-24
EP0765320B1 (fr) 2001-10-10
CA2192975A1 (fr) 1995-12-21
DK0765320T3 (da) 2001-11-26
FI965021A0 (fi) 1996-12-13
DE69523155D1 (de) 2001-11-15
DE69523155T2 (de) 2002-02-07
ATE206708T1 (de) 2001-10-15
FI965021A (fi) 1996-12-13
MX9606450A (es) 1997-03-29
JPH09506637A (ja) 1997-06-30
WO1995034555A1 (fr) 1995-12-21
CA2192975C (fr) 1999-09-21
ES2163506T3 (es) 2002-02-01
EP0765320A1 (fr) 1997-04-02
PT765320E (pt) 2002-02-28

Similar Documents

Publication Publication Date Title
FI113767B (fi) Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
FI970469A (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
AP9701075A0 (en) Spirocyclic dopamine receptor subtype ligands.
ATE152450T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepine und ihre pharmazeutisch verträglichen säureadditionssalze
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
NO970498L (no) Benzimidazolderivater med dopaminergisk aktivitet
ES2181387T3 (es) Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central.
ECSP951500A (es) Derivados de bencimidazol
MX9704299A (es) Derivados de bencimidazol.